Project Grant K99HL186157
Award Date 6/1/26
Completion Date 5/31/28
Dollars Obligated $122K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Ohio State University $249,000 under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on genetic determinants of doxorubicin-induced cardiotoxicity (DIC). The award, effective June 1, 2026, through April 30, 2029, funds an R00 independent research phase that transitions from gene-level perturbation studies to the characterization of specific genetic variants. The...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Ohio State University a Project Grant valued at $1.1 million (awarded July 1, 2026, with completion targeted for June 30, 2033) under the Cardiovascular Diseases Research program (CFDA 93.837). This research initiative investigates the regulation of ubiquitin E3 ligases and innate immunity in Acute Respiratory Distress Syndrome (ARDS), a life-threatening condition with elevated mortality...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Ohio State University a Project Grant valued at $715,378 on August 18, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The grant funds research to elucidate the molecular mechanisms by which cardiac myosin and cardiac myosin-binding protein-C (cMyBP-C) regulate force generation in cardiac muscle contraction. The research will be conducted through a multidisciplinary approach...
- Federal Grant Award Summary The Ohio State University received a $1.53 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 15, 2025, with completion targeted for April 30, 2029. The project, "Engineering an Oxygen-Carrying Perfusate for Normothermic Machine Lung Perfusion," addresses the critical shortage of viable donor lungs for transplantation by developing an engineered...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Pennsylvania a Project Grant totaling $169,020.00 under the Cardiovascular Diseases Research program (CFDA 93.837) beginning August 1, 2025 and concluding June 30, 2027. This research grant funds a comprehensive investigation into the pathophysiologic mechanisms linking obesity and type 2 diabetes to coronary microvascular defects in heart failure with preserved ejection fraction...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Alabama at Birmingham $637,732 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 16, 2025, with completion targeted for June 30, 2029. This Project Grant funds research to develop an engineered therapeutic strategy addressing diabetic ischemic heart failure (IHF), a condition characterized by treatment resistance in diabetic patients. The research focuses on...
- Federal Project Grant Award Summary The Ohio State University received a $156,080 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded on February 19, 2026, with a completion date of September 29, 2026. The award funds research investigating "The Role of NCOA4-Mediated Ferritinophagy in Ozone-Induced Pulmonary Ferroptosis," conducted at the university's Columbus, Ohio campus. This research...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $1,326,945 to the Research Institute at Nationwide Children's Hospital on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate molecular imaging approaches for assessing peripheral artery disease (PAD). The project, extending through May 31, 2029, focuses on developing a dual-phase positron emission tomography/computed tomography (PET/CT)...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Alabama at Birmingham a Project Grant of $535,556 under the Cardiovascular Diseases Research program (CFDA 93.837) effective August 1, 2025, with completion targeted for May 31, 2030. This award supports research to elucidate the role of a novel mechanosensitive histone modification (H3T32 O-GlcNAc) in atherosclerosis pathogenesis. The research investigates how atheroprone shear stress...
- Federal Project Grant Award Summary Albany Medical College received a $586,474 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded June 15, 2026, with completion targeted for February 28, 2030. The research project, titled "Targeting Lipolytic Sterol Signaling to Foster Favorable Foam Cell Modulation and Atheroprotection," will deliver fundamental scientific research investigating...